Earnings Feed
Start Free
Home/Filings/4/0001238303-25-000005
4//SEC Filing

LAROSA JOSEPH J 4

Accession 0001238303-25-000005

CIK 0000872589other
View on SEC.govCompany Profile

Filed

Nov 23, 7:00 PM ET

Accepted

Nov 24, 4:07 PM ET

Size

10.2 KB

Accession

0001238303-25-000005

Insider Transaction Report

Form 4
Period: 2025-11-20
REGENERON PHARMACEUTICALS, INC.REGN
LAROSA JOSEPH J
SVP Gen Counsel and Secretary
Transactions
  • Tax Payment

    Common Stock

    2025-11-20$736.77/sh−12,686$9,346,664→ 22,839 total
  • Exercise/Conversion

    Common Stock

    2025-11-20$555.67/sh+14,450$8,029,431→ 35,525 total
  • Exercise/Conversion

    Non-Qualified Stock Option (right to buy)

    2025-11-20−14,450→ 0 total
    Exercise: $555.67Exp: 2025-12-16→ Common Stock (14,450 underlying)
Holdings

  • Common Stock

    (indirect: By 2024 GRAT)
    9,000

  • Common Stock

    (indirect: By 2025 GRAT)
    9,000

  • Common Stock

    (indirect: By 401(k))
    395
Footnotes (1)
  • [F1]The stock option award vested in four equal annual installments, commencing one year after the date of grant.

Documents

1 file

Issuer

REGENERON PHARMACEUTICALS, INC.

CIK 0000872589

→
Entity typeother

Related Parties

1
  • filerCIK 0001238303

Filing Metadata

Form type
4
Filed
Nov 23, 7:00 PM ET
Accepted
Nov 24, 4:07 PM ET
Size
10.2 KB
View on SEC.gov